Aficamten One More Cardiac Myosin Inhibitor for HOCM

>> DOWNLOAD LINK 🎞️ #1 <<

>> DOWNLOAD LINK 🎞️ #2 <<

>> COPY / PASTE LINK PLEASE 🎵 MP3 <<

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=3KSmegarIRo

Mavacamten is now approved for treatment of symptomatic hypertrophic obstructive cardiomyopathy and endorsed by mult-society guidelines. Now we have Aficamten, next in class cardiac myosin inhibitor for HOCM. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy was published in 2023, with 28 patients on  aficamten 13 on placebo. There was substanital reduction in LVOT gradients and most patients experienced improvement in biomarkers and symptoms. Now a phase 3 trial (SEQUOIA-HCM) of aficamten has been published online • Web: https://johnsonfrancis.org/profession...

#############################